Although not conclusive and possibly dependent on the type of strategy used to elicit anti-leukemia response, these results suggest that important differences may exist among AML patients and further studies are warranted to establish the potential of PRAME as effective target antigen for AML vaccination. This evidence concerns the gene PRAME and acute myeloid leukemia.